RCSI has partnered with Irish medtech company Head Diagnostics to research the use of novel digital biomarkers in monitoring Multiple Sclerosis (MS) on World MS Day. They will assess the handheld medical device iTremor One to measure ocular microtremor (OMT) for objectivity in assessing the condition. Combining this with gait analysis may offer more comprehensive data on disease activity. The observational study at Beaumont Hospital will enroll 120 participants with and without MS to monitor OMT and gait over 12 months. The goal is to provide more precise and robust monitoring of MS for effective management and treatment.
Source link
New study to assess digital MS biomarkers
